BIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the medical technology company’s stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a report on Wednesday, October 2nd.

BIOLASE Stock Performance

Shares of BIOL opened at $0.01 on Tuesday. The stock has a 50 day moving average price of $0.01 and a 200 day moving average price of $0.04. BIOLASE has a one year low of $0.02 and a one year high of $1.94. The stock has a market capitalization of $328,223.78, a price-to-earnings ratio of 0.00 and a beta of 0.67.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.